share_log

聖諾醫藥(02257.HK)完成旗下一項心血管疾病藥物IND準備階段研究

Saint Novo Medicine (02257.HK) completed the IND preparation phase study of a cardiovascular disease drug under its subsidiary.

AASTOCKS ·  Jul 12 12:24

Sanofi-B (02257.HK) announced that it has completed the IND preparation phase study of the target lipid C3 (ApoC3) siRNA therapeutic drug STP125G, which is the second candidate drug based on its proprietary GalAhead mxRNA technology. The safety and efficacy results of non-human primate (NHP) studies strongly support the application of IND to the US FDA to initiate phase I clinical trials of STP125G for cardiovascular disease indications.

The company cannot guarantee that the STP125G drug will ultimately be successfully launched.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment